Copyright investors
On Monday, Kura Oncology (KURA) got an upgrade to its Relative Strength (RS) Rating, from 77 to 84. This exclusive rating from Investor's Business Daily identifies price movement with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database. History reveals that the top-performing stocks typically have an RS Rating north of 80 as they begin their biggest price moves. Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock manages to form a chart pattern and break out. The company posted 0% EPS growth in the latest quarterly report, while sales growth came in at 0%. The company is expected to report its latest numbers on or around Oct. 30. The company holds the No. -1 rank among its peers in the Medical-Biomed/Biotech industry group. This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
